UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
28.58
-0.20 (-0.69%)
At close: May 18, 2026, 4:00 PM EDT
28.60
+0.02 (0.07%)
Pre-market: May 19, 2026, 6:27 AM EDT
UroGen Pharma Employees
UroGen Pharma had 298 employees as of March 31, 2026. The number of employees increased by 64 or 27.35% compared to the same quarter last year.
Employees
298
Change
64
Growth
27.35%
Revenue / Employee
$471,453
Profits / Employee
-$447,064
Market Cap
1.39B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 298 | 64 | 27.35% | 298 | 0 |
| Dec 31, 2025 | 291 | 56 | 23.83% | 291 | 0 |
| Sep 30, 2025 | 287 | 70 | 32.26% | 287 | 0 |
| Jun 30, 2025 | 253 | 50 | 24.63% | 253 | 0 |
| Mar 31, 2025 | 234 | 30 | 14.71% | 234 | 0 |
| Dec 31, 2024 | 235 | 34 | 16.92% | 235 | 0 |
| Sep 30, 2024 | 217 | 25 | 13.02% | 217 | 0 |
| Jun 30, 2024 | 203 | 10 | 5.18% | 203 | 0 |
| Mar 31, 2024 | 204 | 10 | 5.15% | 204 | 0 |
| Dec 31, 2023 | 201 | 1 | 0.50% | 198 | 3 |
| Sep 30, 2023 | 192 | -3 | -1.54% | 192 | 0 |
| Jun 30, 2023 | 193 | -8 | -3.98% | 193 | 0 |
| Mar 31, 2023 | 194 | 2 | 1.04% | 194 | 0 |
| Dec 31, 2022 | 200 | 5 | 2.56% | 200 | 0 |
| Sep 30, 2022 | 195 | -3 | -1.52% | 195 | 0 |
| Jun 30, 2022 | 201 | 11 | 5.79% | 201 | 0 |
| Mar 31, 2022 | 192 | 2 | 1.05% | 192 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Immatics | 711 |
| Immunocore Holdings | 524 |
| Vir Biotechnology | 367 |
| KalVista Pharmaceuticals | 275 |
| Biohaven | 274 |
| Maze Therapeutics | 141 |
| Bicara Therapeutics | 103 |
URGN News
- 3 days ago - UroGen Pharma reports month results from UTOPIA trial - TheFly
- 3 days ago - UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC - GlobeNewsWire
- 5 days ago - UroGen Pharma Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 5 days ago - UroGen Pharma presents 36-month ENVISION trial data - TheFly
- 5 days ago - ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial - GlobeNewsWire
- 7 days ago - UroGen Pharma assumed with a Buy at Ladenburg - TheFly
- 8 days ago - UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright - TheFly
- 11 days ago - UroGen Pharma price target raised to $40 from $34 at Oppenheimer - TheFly